A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin
BackgroundWe conducted this study to evaluate if a reduced cumulative dose of induction and concurrent cisplatin conferred similar favorable outcomes when compared to trial NPC-0501.MethodsNewly diagnosed nasopharyngeal carcinoma (NPC) with stage III-IVA were prospectively recruited from January 201...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.842281/full |
| _version_ | 1818047523259940864 |
|---|---|
| author | Zhiyuan Xu Zhiyuan Xu Li Yang Wai-Tong Ng Wai-Tong Ng Aya El Helali Aya El Helali Victor Ho-Fun Lee Victor Ho-Fun Lee Lingyu Ma Qin Liu Jishi Li Lin Shen Jijie Huang Jiandong Zha Cheng Zhou Anne W. M. Lee Anne W. M. Lee Longhua Chen |
| author_facet | Zhiyuan Xu Zhiyuan Xu Li Yang Wai-Tong Ng Wai-Tong Ng Aya El Helali Aya El Helali Victor Ho-Fun Lee Victor Ho-Fun Lee Lingyu Ma Qin Liu Jishi Li Lin Shen Jijie Huang Jiandong Zha Cheng Zhou Anne W. M. Lee Anne W. M. Lee Longhua Chen |
| author_sort | Zhiyuan Xu |
| collection | DOAJ |
| description | BackgroundWe conducted this study to evaluate if a reduced cumulative dose of induction and concurrent cisplatin conferred similar favorable outcomes when compared to trial NPC-0501.MethodsNewly diagnosed nasopharyngeal carcinoma (NPC) with stage III-IVA were prospectively recruited from January 2015 to September 2019. Induction chemotherapy (IC) consisted of cisplatin 80mg/m2 on day 1 and capecitabine 1000mg/m2 twice daily from day 1 to 14 every 3 weeks for 3 cycles followed by concurrent chemoradiotherapy (CCRT) with 2 cycles of cisplatin 100mg/m2 given every 3 weeks. Tumor response was evaluated according to RECIST v1.1. Acute and late adverse events (AEs) were graded with CTCAE v4.0 and Late Radiation Morbidity Scoring of the RTOG, respectively.Results135 patients were recruited. At 16 weeks after CCRT, all 130 patients who completed the entire course of radiotherapy (RT) had a complete response upon final assessment. With a median follow-up of 36.2 months, 22 treatment failures and 8 deaths were observed. The 3-year progression-free survival, overall survival, locoregional recurrence-free survival, and distant recurrence-free survival were 83.7%, 94.1%, 94.1%, and 85.9%, respectively. Our survival data outcomes were similar to those reported in the cisplatin and capecitabine (PX) induction arm of the 0501 trial. 103 patients (76.3%) reported acute grade 3-4 AEs. Two patients (1.5%) had late grade 3-4 complications, numerically fewer than those reported in the NPC-0501 trial.ConclusionsInduction PX and concurrent cisplatin with a reduced cumulative cisplatin dose yield survival outcomes comparable to those reported in the NPC-0501 trial with excellent tolerability. Therefore, a reduced cumulative dose of cisplatin is a promising treatment scheme for nasopharyngeal carcinoma. |
| first_indexed | 2024-12-10T10:07:08Z |
| format | Article |
| id | doaj.art-7f22d18e4520460f9f9ee47e913589c4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T10:07:08Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-7f22d18e4520460f9f9ee47e913589c42022-12-22T01:53:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.842281842281A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of CisplatinZhiyuan Xu0Zhiyuan Xu1Li Yang2Wai-Tong Ng3Wai-Tong Ng4Aya El Helali5Aya El Helali6Victor Ho-Fun Lee7Victor Ho-Fun Lee8Lingyu Ma9Qin Liu10Jishi Li11Lin Shen12Jijie Huang13Jiandong Zha14Cheng Zhou15Anne W. M. Lee16Anne W. M. Lee17Longhua Chen18Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong KongSAR, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong KongSAR, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong KongSAR, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaClinical Oncology Centre, The University of Hong Kong - Shenzhen Hospital, Shenzhen, ChinaDepartment of Clinical Oncology, The University of Hong Kong, Hong Kong, Hong KongSAR, ChinaDepartment of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, ChinaBackgroundWe conducted this study to evaluate if a reduced cumulative dose of induction and concurrent cisplatin conferred similar favorable outcomes when compared to trial NPC-0501.MethodsNewly diagnosed nasopharyngeal carcinoma (NPC) with stage III-IVA were prospectively recruited from January 2015 to September 2019. Induction chemotherapy (IC) consisted of cisplatin 80mg/m2 on day 1 and capecitabine 1000mg/m2 twice daily from day 1 to 14 every 3 weeks for 3 cycles followed by concurrent chemoradiotherapy (CCRT) with 2 cycles of cisplatin 100mg/m2 given every 3 weeks. Tumor response was evaluated according to RECIST v1.1. Acute and late adverse events (AEs) were graded with CTCAE v4.0 and Late Radiation Morbidity Scoring of the RTOG, respectively.Results135 patients were recruited. At 16 weeks after CCRT, all 130 patients who completed the entire course of radiotherapy (RT) had a complete response upon final assessment. With a median follow-up of 36.2 months, 22 treatment failures and 8 deaths were observed. The 3-year progression-free survival, overall survival, locoregional recurrence-free survival, and distant recurrence-free survival were 83.7%, 94.1%, 94.1%, and 85.9%, respectively. Our survival data outcomes were similar to those reported in the cisplatin and capecitabine (PX) induction arm of the 0501 trial. 103 patients (76.3%) reported acute grade 3-4 AEs. Two patients (1.5%) had late grade 3-4 complications, numerically fewer than those reported in the NPC-0501 trial.ConclusionsInduction PX and concurrent cisplatin with a reduced cumulative cisplatin dose yield survival outcomes comparable to those reported in the NPC-0501 trial with excellent tolerability. Therefore, a reduced cumulative dose of cisplatin is a promising treatment scheme for nasopharyngeal carcinoma.https://www.frontiersin.org/articles/10.3389/fonc.2022.842281/fullnasopharyngeal carcinomainduction chemotherapycisplatincapecitabineprogression-free survival |
| spellingShingle | Zhiyuan Xu Zhiyuan Xu Li Yang Wai-Tong Ng Wai-Tong Ng Aya El Helali Aya El Helali Victor Ho-Fun Lee Victor Ho-Fun Lee Lingyu Ma Qin Liu Jishi Li Lin Shen Jijie Huang Jiandong Zha Cheng Zhou Anne W. M. Lee Anne W. M. Lee Longhua Chen A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin Frontiers in Oncology nasopharyngeal carcinoma induction chemotherapy cisplatin capecitabine progression-free survival |
| title | A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin |
| title_full | A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin |
| title_fullStr | A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin |
| title_full_unstemmed | A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin |
| title_short | A Single-Arm Phase 2 Trial on Induction Chemotherapy Followed by Concurrent Chemoradiation in Nasopharyngeal Carcinoma Using a Reduced Cumulative Dose of Cisplatin |
| title_sort | single arm phase 2 trial on induction chemotherapy followed by concurrent chemoradiation in nasopharyngeal carcinoma using a reduced cumulative dose of cisplatin |
| topic | nasopharyngeal carcinoma induction chemotherapy cisplatin capecitabine progression-free survival |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.842281/full |
| work_keys_str_mv | AT zhiyuanxu asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT zhiyuanxu asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT liyang asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT waitongng asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT waitongng asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT ayaelhelali asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT ayaelhelali asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT victorhofunlee asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT victorhofunlee asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT lingyuma asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT qinliu asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT jishili asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT linshen asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT jijiehuang asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT jiandongzha asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT chengzhou asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT annewmlee asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT annewmlee asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT longhuachen asinglearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT zhiyuanxu singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT zhiyuanxu singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT liyang singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT waitongng singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT waitongng singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT ayaelhelali singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT ayaelhelali singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT victorhofunlee singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT victorhofunlee singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT lingyuma singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT qinliu singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT jishili singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT linshen singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT jijiehuang singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT jiandongzha singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT chengzhou singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT annewmlee singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT annewmlee singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin AT longhuachen singlearmphase2trialoninductionchemotherapyfollowedbyconcurrentchemoradiationinnasopharyngealcarcinomausingareducedcumulativedoseofcisplatin |